EUVIMEDDescobrir EUVIMED
Open access · CC BY 4.0

Bias in Meta‐Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials

James P Long iD, Abhishikta Roy, Ehsan Irajizad, Kim-Anh Do, Yu Shen

Statistics in Medicine · 2026

DOI: 10.1002/sim.70731 ↗

At a glance

Journal article in Statistics in Medicine, 2026. Written by James P Long and 4 co-authors. Institution: University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Major MEDLINE topics: Meta-Analysis as Topic, Models, Statistical, Early Detection of Cancer, Clinical Trials as Topic. 42 references. The full text is freely available (open access, CC BY 4.0). Funded by: NCATS NIH HHS, NCI NIH HHS, National Cancer Institute.

ResumoSubjectsDados bibliográficosCiteRelated studies

Abstract (original language)

In meta‐analytic modeling, the functional relationship between a primary and surrogate endpoint is estimated using summary data from a set of completed clinical trials. Parameters in the meta‐analytic model are used to assess the quality of the proposed surrogate. Recently, meta‐analytic models have been employed to evaluate whether late‐stage cancer incidence can serve as a surrogate for cancer mortality in cancer screening trials. A major challenge in meta‐analytic models is that uncertainty of trial‐level estimates affects the evaluation of surrogacy, since each trial provides only estimates of the primary and surrogate endpoints rather than their true parameter values. In this work, we show via simulation and theory that trial‐level estimate uncertainty may bias the results of meta‐analytic models toward positive findings of the quality of the surrogate. We focus on cancer screening trials and the late‐stage incidence surrogate. We reassess correlations between primary and surrogate endpoints in Ovarian cancer screening trials. Our findings indicate that completed trials provide limited information regarding quality of the late‐stage incidence surrogate. These results support restricting meta‐analytic regression usage to settings where trial‐level estimate uncertainty is incorporated into the model.

Subjects

MeSH terms (MEDLINE)

Meta-Analysis as TopicModels, StatisticalEarly Detection of CancerClinical Trials as TopicBiomarkersHumansFemaleOvarian NeoplasmsBiasComputer SimulationUncertainty

Substances

Biomarkers

Authors and institutions

  • University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • University of Texas School of Public Health, Houston, Texas, USA.

ORCID profiles: James P Long

Funding

  • NCATS NIH HHS
  • NCI NIH HHS
  • National Cancer Institute
  • National Center for Advancing Translational Sciences

Cite

APA

Long, J. P., Roy, A., Irajizad, E., Do, K. A., & Shen, Y. (2026). Bias in Meta‐Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials. Statistics in Medicine. https://doi.org/10.1002/sim.70731

Vancouver

Long JP, Roy A, Irajizad E, Do KA, Shen Y. Bias in Meta‐Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials. Statistics in Medicine. 2026. doi:10.1002/sim.70731

BibTeX
@article{Long2026,
  author = {Long, James P and Roy, Abhishikta and Irajizad, Ehsan and Do, Kim-Anh and Shen, Yu},
  title = {Bias in Meta‐Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials},
  journal = {Statistics in Medicine},
  year = {2026},
  doi = {10.1002/sim.70731}
}
Start for free →